Enk Alexander, Fierlbeck Gerhard, French Lars, Hertl Michael, Messer Gerald, Meurer Michael, Steinbrink Kerstin, Stingl Georg, Volc-Platzer Beatrice, Zillikens Detlef
J Dtsch Dermatol Ges. 2009 Sep;7(9):806-812. doi: 10.1111/j.1610-0387.2009.07118.x.
The treatment of severe autoimmune skin diseases and of toxic epidermal necrolysis (ICD: L51.2) with high-dose intravenous immunoglobulins (IVIg) is an established therapeutic procedure in dermatology. As IVIg are usually only administered in rare autoimmune diseases or in particularly severe disease courses, use of immunoglobulins in dermatology is commonly not based on experience from controlled and randomized studies typically demanded by evidence-based medicine. In face of the rarity of indications for IVIg it is improbable that such studies will be performed in the foreseeable future. Further, as the high costs of IVIg treatment limits its use as first-line therapy, no clear guidelines exist yet on IVIg use in skin diseases. The present recommendation is based on a consensus of the Working Group on European Guidelines of the EDF (European Dermatology Forum) and the EADV (European Association of Dermato-Venereology) and should provide aid in decision making for the use of IVIg in treating dermatologic diseases
大剂量静脉注射免疫球蛋白（IVIg）治疗严重自身免疫性皮肤病和中毒性表皮坏死松解症（ICD：L51.2）是皮肤科既定的治疗方法。由于IVIg通常仅用于罕见的自身免疫性疾病或特别严重的病程，皮肤科使用免疫球蛋白通常并非基于循证医学通常要求的对照和随机研究经验。鉴于IVIg适应症罕见，在可预见的未来不太可能进行此类研究。此外，由于IVIg治疗成本高昂限制了其作为一线治疗的应用，目前尚无关于在皮肤病中使用IVIg的明确指南。本推荐基于欧洲皮肤病论坛（EDF）和欧洲皮肤性病学协会（EADV）欧洲指南工作组的共识，应为使用IVIg治疗皮肤病的决策提供帮助。
